Latest Breaking News On - Clinical trial design - Page 1 : vimarsana.com

Top Kidney Patient Group Shares National Reuters Pharma Award

/PRNewswire/ The American Association of Kidney Patients (AAKP), the oldest and largest independent kidney patient organization in the U.S., and Bayer were.

United statesUniversity of washingtonNew marketDepartment of defenseReuters pharma award in driving health equityUniversity of minnesota hennepin healthcare research instituteUniversity of pittsburghCenters for diseasePatient researchHealth resourcesNational institutes of healthNorthwestern universityVanderbilt universityCenters for medicareOrder on advancing american kidney healthHealth sciences

4th Annual Psychedelic Therapeutics and Drug Development Conference Scheduled for May 23-24 in Boston, MA

4th Annual Psychedelic Therapeutics and Drug Development Conference Scheduled for May 23-24 in Boston, MA
businessinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from businessinsider.com Daily Mail and Mail on Sunday newspapers.

United statesAlan kozikowskiDeborah mashCharles nicholsLos angelesPurminds neuropharmaPeter hendricksBernard lererDrug development conferencePrecision medicine to mental health careUniversity of alabama birminghamLegal challenges in researchCorporate communicationsReimagining the framework for psychedelic researchHebrew universityRevere hotel boston common

Praxis Precision Medicines to Present on Ulixacaltamide at the American Academy of Neurology 2024 Annual Meeting

BOSTON, April 12, 2024 (GLOBE NEWSWIRE) Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translati.

Colorado convention centerUnited statesMarcio souzaAmerican academy of neurologyPraxis precision medicines incExchange commissionProgram to evaluate the efficacyTremor programPrecision medicinesAmerican academyColorado conventionClinical trial designExhibit hallNeurologic care industry presentationDecentralized phasePraxi phase

Algernon Pharmaceuticals to Move Forward with Psychedelic Drug DMT Stroke Research Program as its Lead Asset

VANCOUVER, British Columbia, April 01, 2024 (GLOBE NEWSWIRE) Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian clinical stage pharmaceutical development company, is pleased to announce that it plans to move forward with its intravenous formulation of its AP-188 (“N,N-Dimethyltryptamine” or “DMT”) stroke research program as its lead asset, after having sold its Ifenprodil research program for USD $2M cash and a 20% common share

British columbiaUnited kingdomChristopherj moreauCompany or algernonAlgernon pharmaceuticalsAlgernon pharmaceuticals incCentre for human drug researchCompany phaseAlgernon neuroscienceStroke studyHuman drug researchAlgernon pharmaceuticals incClinical trial designResearch programAlgernon neuroscience

Limb-Girdle Muscular Dystrophy Leaders Advance Collaborative Dialogue to Accelerate Drug Development to Address the Urgent Unmet Need in Limb-Girdle Muscular Dystrophy

/PRNewswire/ On February 8, 2024, The Speak Foundation, a patient-led 501(c)(3) organization for Limb-Girdle Muscular Dystrophy (LGMD), convened a.

United statesDouglas sprouleMichelle campbellMatthew wicklundJannie kennedyKatherine mathewsKathryn bryant knudsonNicholas johnsonPeter marksLouise rodino klapacNicole verdunLindsay alfanoPeter kangPeter steinJames signorovitchJerryr mendell